Ernest Newman, A. B., A. T. Johnson, Nicolas Bentley, Sir Ernest Barker, O. H. Brandon Sunday Times Representative, A. V. C, Yarborough, H. M. Simmons, W. Kay Robinson, Chris Bale, Ralph Straus, Charles Morgan, M. J. S, Sir Arthur Griffith-Boscawen, O. R. Holms, Eric Newton, Norman Crump City Editor, James Agate, C. V. Wedgwood, A. E. Webb, C. T. Jenner, D. R. Gent, Desmond MacCarthy, G. L. Schwartz, Atticus, Richard Strout Representative of The Sunday Times, William Dale, R. Kujala, J. H. Higginson, Frank MacDermot Representative of The Sunday Times, Archibald Gibson Sunday Times Representative, E. Colston Shepherd Sunday Times Air Correspondent, Arthur Bryant, Edward Shanks, Dilys Powell, B. R. Gibbs, Rev. Robert F. V. Scott, Dr. Geoffrey Evans, Styx, Arnold Vas Dias Sunday Times Special Representative, O. H. Brandon The Sunday Times Representative,
... Paul L. Stein. (Warner) La Symphonie Fantastique. Director: Christian-Jacque. (Curzon) Without Dowry. Director: Y. Protoxanov. (Tatler) Do ...
1946 - Gale Group | Sunday Times HA GDA
Michel Soulard, V. Della Valle, Mikkiko C. Siomi, Serafı́n Piñol-Roma, Patrice Codogno, Chantal Bauvy, Michel Bellini, J. C. Lacroix, Guillaume Monod, Gidden Dreyfuss, Christian‐Jacques Larsen,
... on: Oxford Academic PubMed Google Scholar ... Show more Christian-Jacques Larsen Christian-Jacques Larsen * * To whom correspondence should be addressed Search ...
Tópico(s): Viral Infections and Immunology Research
1993 - Oxford University Press | Nucleic Acids Research
Olivier Corbeil, Stéphanie Corbeil, Michel Dorval, Pierre‐Hugues Carmichael, Isabelle Giroux, Christian Jacques, Marie‐France Demers, Marc‐André Roy,
Tópico(s): Mental Health and Psychiatry
2021 - Adis, Springer Healthcare | CNS Drugs
David Lévesque, Serge Sévigny, Isabelle Giroux, Christian Jacques,
Tópico(s): Sexuality, Behavior, and Technology
2018 - Springer Science+Business Media | Journal of Gambling Studies
Laurent Beaugerie, Fabrice Carrat, Stéphane Nahon, Jean‐David Zeitoun, Jean‐Marc Sabaté, Laurent Peyrin–Biroulet, Jean–Frédéric Colombel, Matthieu Allez, Jean–François Fléjou, Julien Kirchgesner, Magali Svrcek, Jean–Frédéric Colombel, Jacques Cosnes, Jean–Pierre Gendre, Marc Lémann, Xavier Hébuterne, Antoine Cortot, Yoram Bouhnik, David Laharie, Jean Louis Dupas, Bernard Flourié, Éric Lerebours, Laurent Beaugerie, Laurent Peyrin–Biroulet, Matthieu Allez, Bernard Messing, Guillaume Cadiot, Philippe Marteau, Jean–Claude Soulé, Jean‐Marc Gornet, M Veyrac, Bernard Duclos, Philippe Beau, Arnaud Bourreille, P. Bäumer, Franck Carbonnel, D. Héresbach, Étienne-Henry Metman, C Florent, Antoine Blain, Jean‐Luc Faucheron, Bruno Bonaz, Xavier Roblin, Pascal Potier, Christian R. Boehm, Thierry Kurtz, H Lamouliatte, Isabelle Nion–Larmurier, Jean‐Charles Delchier, Stanislas Chaussade, Anne Marie Weiss, J.P. Cézard, Laurent Siproudhis, Stéphane Nahon, Daniel Sondag, Raymond Jian, Jean-Christophe Souquet, Pierre Bord, Benoît Coffin, H d’Almagne, Patrick Delasalle, Régis Fournier, Maryan Cavicchi, M. Souffran, Luc Vandromme, C Guédon, Philippe Seksik, Christophe Michiels, Pascal Renard, Patrice Rogier, S Gouilloud, André Rotenberg, Guillaume Savoye, A Thévenin, Laurent Mallet, Franck Brazier, F. Jean, Anne‐Marie Justum, Jean‐Paul Latrive, J. L. Gerbal, R Pierrugues, Gérard Chardonnal, Laurence Picon, N Reix, N d'Aubigny, Hervé Uettwiller, Anne Courillon Mallet, Alain Palacci, R. Bensaude, Pierre Bonniaud, Olivier Empinet, A Nisard, A. Rudelli, B Tubiana, P Capelle, A. Dabadie, D Evard, Pierre-Emile Julien, Magali Picon-Coste, S. Schneider, D Goldfain, J Bellanger, Jean-Pierre Blondelot, Philippe Lamy, Sébastien Lemière, Jean Francois Mockly, Benoit Pellat, Gilles Gatineau-Sailliant, Bernard Nalet, Stéphane Nancey, D Kusielewicz, P. Loison, Jean-Michel Popot, F Merite, Jean-Pol Roux, Pauline Afchain, A Blanquart, Laurent Heyries, Marc Reville, Dominique Viron, Frank Zerbib, Christophe Clavière, Didier Léostic, Philippe Pouderoux, Alain Moitry, Hervé Hagège, Jean‐Pierre Hugot, Benoît Humeau, Jean‐Marc Sabaté, Emmanuel Lederman, D. Lescut, Fabrice Luneau, B Mesnard, Lionel Smadja, Michel Steinberg, Marc Brun, Gilles Macaigne, Jean Luc Marchal, Stéphane Ollivier, D Ouvry, Jean Paul Perche, S Rambaud, Robert Benamouzig, Jean Louis Cazenave, Jean-Charles Coffin, Martine Blazquez, Marion Lagneau, Bruno Person, Christian Wittersheim, Bertrand Napoléon, I Cemachovic, F. Iglicki, Mehran Howaizi, Eric Leprince, Bruno Leurent, Thierry Morin, Riad Darsouni, Alain Attar, Philippe Baron, Anne Breton, J M Gillion, Jean-Marc Guemene, C Jouffre, Xavier Moreau, Pierre Claudé, André Quinton, Véred Abitbol, Jean Michel Brichard, B Desaint, Martin Bouygues, P Chatrenet, Marcelo Salmeron, J Silvie, Bruno Waldner, Yves Emery, Armand Moraillon, Daniel Kunkel, Philippe Dubois, Patrick Fauré, C L'Hirondel, Jean-Eric Labérenne, Pierre Moreau, Adelino Pereira, Genevieve Plihon, Thierry Wolff, Yann Ngô, Arnaud Boruchowicz, B Jost, Jean Pierre Gotlib, O Danne, Philippe Raoux, Marie-José Ramond-Bouhali, A Baetz, Bruno Veyres, C Chapoutot, Gérard Le Dréau, Jérôme Filippi, J Mudry, Philippe Kalt, S Minault, Pierre-André Bounin, Tony Andréani, J Charneau, Didier Reijasse, Jean-Louis Bolze, Jean Luc Thaunat, C Le Couteulx, C. Maurage, Robert Bader, Philippe Codjovi, Jean-Luc Migairou, A. Morali, Philippe Rey, B Richard Molard, Richard E. Petit, Stéphane Koch, Philippe Cassan, J Deschamps, Christine Meicler Caby, J.J. Meurisse, P Prades, James Boulant, Michel Diacono, J. M. MONSCH, J-François Dupuy, Guy Bellaïche, Martine Guegan, Jean-Marc Comte, Jean-Michel Cayla, Francois Le Tallec, F Meurisse, Philippe Desurmont, L Roget, Philippe Bouyssou, Bruno Le Gall, Francis Bloch, L Larvol, Monique Jullien, Jacques Moreau, Laurent Rebouissoux, Bruno Decroix, Nina Dib, Paul Dieterling, Frédéric Lenormand, E. Lagier, Philippe Fallourd, Serge Charpin, Hugues Bertrand, Gilles Bommelaer, Daniel Battistelli, Bernard Delon, L Dentant, Étienne Dorval, Jérôme Dumortier, Eric Gaye-Bareyt, Yves Gerosa, C Guez, M Mornet, Paul Benfredj, René Piperaud, Noël Stremsdoerfer, Eric Verdier, Alain Grinholtz, Georges Barjonet, A. T. A. See, Ramuntxo Arotçarena, A Baudet, Joël Broyer, Antoine Charachon, H. Blondon, Pascal Mouton, Hubert Claudez, Jacques Labat-Labourdette, J. Haem, P. Estable, Patrick Lévy, Alain Rosenbaum, Yvon Balavoine, A Blanchi, Pierre Coutarel, N. Delapérrière, M Dervichian, Francis Marois, Jacques Seroka, L. Michaud, O. Leroy, Emmanuel Meyran, Bernard Poilroux, Abdallah Tensaouti, Thierry Paupard, D Agard, Sandrine Beaulieu, K Benfiguig, P Capony, Jean Cottereau, Pierre Desreumaux,
Little is known about the magnitude of the risk of anal and rectal cancer in patients with anal and/or perineal Crohn's disease. We aimed to assess the risk of anal and rectal cancer in patients with Crohn's perianal disease followed up in the Cancers Et Surrisque Associé aux Maladies Inflammatoires Intestinales En France (CESAME) cohort.We collected data from 19,486 patients with inflammatory bowel disease (IBD) enrolled in the observational CESAME study in France, from May 2004 through June 2005; ...
Elsevier BV
David Lévesque, Serge Sévigny, Isabelle Giroux, Christian Jacques,
The Gambling-Related Cognition Scale (GRCS; Raylu & Oei, 2004) was developed to evaluate gambling-related cognitive distortions for all types of gamblers, regardless of their gambling activities (poker, slot machine, etc.). It is therefore imperative to ascertain the validity of its interpretation across different types of gamblers; however, some skills-related items endorsed by players could be interpreted as a cognitive distortion despite the fact that they play skills-related games. Using an intergroup ( ...
Tópico(s): Sports Analytics and Performance
2017 - American Psychological Association | Psychology of Addictive Behaviors
Isabelle Giroux, Annie Goulet, Jonathan Mercier, Christian Jacques, Stéphane Bouchard,
Online interventions for gambling, alcohol, and illegal drug related problems have been developing at a fast pace over the past decade. Yet, little is known about the content and efficacy of interventions provided entirely online for reducing drug/alcohol use and gambling, or about the characteristics of those who use these interventions. This systematic review aims to describe the characteristics of online interventions, their efficacy, and the profile of their clientele. Documentation was mainly ...
Tópico(s): Sexuality, Behavior, and Technology
2017 - Frontiers Media | Frontiers in Psychology
Stéphane Bouchard, Geneviève Robillard, Isabelle Giroux, Christian Jacques, Claudie Loranger, Manon St-Pierre, Maxime Chrétien, Annie Goulet,
Virtual reality (VR) can be used in the treatment of gambling disorder to provide emotionally charged contexts (e.g., induce cravings) where patients can practice cognitive behavior therapy (CBT) techniques in the safety of the therapist's office. This raises practical questions, such as whether the cravings are sufficient to be clinically useful but also manageable enough to remain clinically safe. Pilot data are also needed to test the development of a treatment manual and prepare large randomized ...
Tópico(s): Personality Disorders and Psychopathology
2017 - Frontiers Media | Frontiers in Psychiatry
Maxime Chrétien, Isabelle Giroux, Annie Goulet, Christian Jacques, Stéphane Bouchard,
Gamblers' thoughts have a fundamental influence on their gambling problem. Cognitive restructuring is the intervention of choice to correct those thoughts. However, certain difficulties are noted in the application of cognitive restructuring techniques and the comprehension of their guidelines. Furthermore, the increase of skill game players (e.g. poker) entering treatment creates a challenge for therapists, as these gamblers present with different thoughts than those of the gamblers usually encountered ...
Tópico(s): Schizophrenia research and treatment
2017 - Elsevier BV | Addictive Behaviors
Aurélie Mouneyrac, Céline Lemercier, Valérie Le Floch, Gaëlle Challet‐Bouju, Axelle Moreau, Christian Jacques, Isabelle Giroux,
Participation in strategic and non-strategic games is mostly explained in the literature by gender: men gamble on strategic games, while women gamble on non-strategic games. However, little is known about the underlying cognitive factors that could also distinguish strategic and non-strategic gamblers. We suggest that cognitive style and need for cognition also explain participation in gambling subtypes. From a dual-process perspective, cognitive style is the tendency to reject or accept the fast, ...
Tópico(s): Sports Analytics and Performance
2017 - Springer Science+Business Media | Journal of Gambling Studies
K. Weisel, Meletios Α. Dimopoulos, Philippe Moreau, Martha Q. Lacy, Kevin Song, M. Delforge, Lionel Karlin, Hartmut Goldschmidt, A. Baños, Albert Oriol, Adrián Alegre, C. Chen, Michèle Cavo, Laurent Garderet, V. L. Ivanova, Joaquín Martínez‐López, Stefan Knop, Xiaoyan Yu, Kevin Hong, Lars Sternås, Christian Jacques, Mohamed H. Zaki, Jesús F. San Miguel,
Pomalidomide + low-dose dexamethasone is effective and well tolerated for refractory or relapsed and refractory multiple myeloma after bortezomib and lenalidomide failure. The phase III trial MM-003 compared pomalidomide + low-dose dexamethasone with high-dose dexamethasone. This subanalysis grouped patients by baseline creatinine clearance ≥ 30 − < 60 mL/min (n=93, pomalidomide + low-dose dexamethasone; n=56, high-dose dexamethasone) or ≥ 60 mL/min (n=205, pomalidomide + low-dose dexamethasone; n=93, high-dose dexamethasone). ...
Tópico(s): Protein Degradation and Inhibitors
2016 - Ferrata Storti Foundation | Haematologica
Meletios Α. Dimopoulos, MT Petrucci, Robin Foà, J. Catalano, Martin Kropff, Evangelos Terpos, Jianqi Zhang, Ludger Grote, Christian Jacques, A. Palumbo,
Maintenance therapy has generally been shown to improve outcomes in newly diagnosed multiple myeloma (NDMM).1–8 Increases in progression-free survival (PFS) and overall survival (OS) have been demonstrated in some trials of maintenance therapy,4–6 but others have reported improved PFS with no corresponding improvement in OS.1–3 The lack of OS benefit may be due to crossover and insufficient follow-up, as well as the fact that these trials were not powered to detect differences in OS between treatment ...
Tópico(s): Peptidase Inhibition and Analysis
2015 - Ferrata Storti Foundation | Haematologica
Antonio Palumbo, Francesca Gay, Federica Cavallo, Francesco Di Raimondo, Alessandra Larocca, Izhar Hardan, Arnon Nagler, Maria Teresa Petrucci, Roman Hájek, Sara Pezzatti, Michel Delforge, Francesca Patriarca, Francesca Donato, Chiara Cerrato, Chiara Nozzoli, Zhinuan Yu, Luana Boccadifuoco, Tommaso Caravita, Giulia Benevolo, Tommasina Guglielmelli, Donatella Vincelli, Christian Jacques, Meletios Α. Dimopoulos, Giovannino Ciccone, Pellegrino Musto, Paolo Corradini, Michèle Cavo, Mario Boccadoro,
Purpose Continuous therapy (CT) prolongs progression-free survival 1 (PFS1; time from random assignment until the first progression or death), but chemotherapy-resistant relapse may negatively impact overall survival (OS). Progression-free survival 2 (PFS2; time from random assignment until the second progression or death) may represent an additional tool to estimate outcome. This study evaluates the benefit of novel agent–based CT versus fixed duration of therapy (FDT) in patients with newly diagnosed ...
Tópico(s): Cancer Treatment and Pharmacology
2015 - Lippincott Williams & Wilkins | Journal of Clinical Oncology
Meletios Α. Dimopoulos, K. Weisel, Kevin Song, Michel Delforge, Lionel Karlin, Hartmut Goldschmidt, Philippe Moreau, A. Baños, Albert Oriol, L. Garderet, Michèle Cavo, V. L. Ivanova, Adrián Alegre, Joaquín Martínez‐López, Christopher Chen, Andrew Spencer, Stefan Knop, Nizar J. Bahlis, Christoph Renner, Xin Yu, Kevin Hong, Lars Sternås, Christian Jacques, Mohamed H. Zaki, Jesús F. San Miguel,
Patients with refractory or relapsed and refractory multiple myeloma who no longer receive benefit from novel agents have limited treatment options and short expected survival. del(17p) and t(4;14) are correlated with shortened survival. The phase 3 MM-003 trial demonstrated significant progression-free and overall survival benefits from treatment with pomalidomide plus low-dose dexamethasone compared to high-dose dexamethasone among patients in whom bortezomib and lenalidomide treatment had failed. ...
Tópico(s): Cancer Treatment and Pharmacology
2015 - Ferrata Storti Foundation | Haematologica
Christian Jacques, Daniel Fortin‐Guichard, Pierre-Yves Bergeron, Catherine Boudreault, David Lévesque, Isabelle Giroux,
Some Facebook games are offered by developers who also offer gambling games, possibly indicating that gambling content (GC) could be found in their Facebook games. This study measures the presence of GC in Facebook games and documents their presentation. It verifies whether GC is more present in games offered by developers offering gambling games as well. The 100 most popular Facebook games were played for 10 min and recorded for content analysis purposes. GC was detected and classified into standard ...
Tópico(s): Video Analysis and Summarization
2015 - Elsevier BV | Computers in Human Behavior
Jesús F. San Miguel, K. Weisel, Kevin Song, M. Delforge, Lionel Karlin, Hartmut Goldschmidt, Philippe Moreau, A. Baños, Albert Oriol, L. Garderet, Michèle Cavo, V. Ivanova, Adrián Alegre, Joaquin Martínez‐López, C. Chen, Christoph Renner, NJ Bahlis, Xiaoyan Yu, T. A. Teasdale, Lars Sternås, Christian Jacques, Mohamed H. Zaki, Meletios Α. Dimopoulos,
Pomalidomide is a distinct oral IMiD® immunomodulatory agent with direct antimyeloma, stromal-support inhibitory, and immunomodulatory effects. The pivotal, multicenter, open-label, randomized phase 3 trial MM-003 compared pomalidomide + low-dose dexamethasone vs high-dose dexamethasone in 455 patients with refractory or relapsed and refractory multiple myeloma after failure of bortezomib and lenalidomide treatment. Initial results demonstrated significantly longer progression-free survival and overall ...
Tópico(s): Protein Degradation and Inhibitors
2015 - Ferrata Storti Foundation | Haematologica
Katja Weisel, Meletios Α. Dimopoulos, Kevin Song, Philippe Moreau, Antonio Palumbo, Andrew R. Belch, Stephen Schey, Pieter Sonneveld, Lars Sternås, Xin Yu, Ramesh Amatya, Craig J. Gibson, Mohamed H. Zaki, Christian Jacques, Jesús F. San Miguel,
Background Health-related quality of life (HRQoL) is an important element for consideration in treatment decisions in patients with relapsed/refractory multiple myeloma (RRMM). The pivotal MM-003 (A Phase 3, Multicenter, Randomized, Open-Label Study to Compare the Efficacy and Safety of Pomalidomide in Combination With Low-Dose Dexamethasone vs. High-Dose Dexamethasone in Patients With Refractory Multiple Myeloma or Relapsed and Refractory Multiple Myeloma and Companion Study [NIMBUS]) randomized, open- ...
Tópico(s): Cancer Treatment and Pharmacology
2015 - Elsevier BV | Clinical Lymphoma Myeloma & Leukemia
Lotfi Benboubker, Meletios Α. Dimopoulos, Angela Dispenzieri, John Catalano, Andrew R. Belch, Michèle Cavo, Antonio Pinto, Katja Weisel, Heinz Ludwig, Nizar J. Bahlis, Anne Banos, Mourad Tiab, Michel Delforge, Jamie Cavenagh, Catarina Geraldes, Je‐Jung Lee, Christine Chen, Albert Oriol, Javier de la Rubia, Lugui Qiu, Darrell White, Daniel Binder, Kenneth Anderson, Jean-Paul Fermand, Philippe Moreau, Michel Attal, Robert Knight, Guang Chen, Jason Van Oostendorp, Christian Jacques, Annette Ervin‐Haynes, Hervé Avet‐Loiseau, Cyrille Hulin, Thierry Façon,
The combination melphalan-prednisone-thalidomide (MPT) is considered a standard therapy for patients with myeloma who are ineligible for stem-cell transplantation. However, emerging data on the use of lenalidomide and low-dose dexamethasone warrant a prospective comparison of the two approaches.We randomly assigned 1623 patients to lenalidomide and dexamethasone in 28-day cycles until disease progression (535 patients), to the same combination for 72 weeks (18 cycles; 541 patients), or to MPT for 72 ...
Tópico(s): Protein Degradation and Inhibitors
2014 - Massachusetts Medical Society | New England Journal of Medicine
Gareth J. Morgan, Antonio Palumbo, Sujith Dhanasiri, Dawn Lee, Katja Weisel, Thierry Façon, Michel Delforge, Albert Oriol, Mohamed H. Zaki, Xin Yu, Lars Sternås, Christian Jacques, Ron Akehurst, Fritz Offner, Meletios Α. Dimopoulos,
Summary In the phase III MM ‐003 trial, pomalidomide plus low‐dose dexamethasone ( POM +Lo DEX ) improved overall survival ( OS ) versus high‐dose dexamethasone (Hi DEX ) in 455 patients with relapsed and refractory multiple myeloma ( RRMM ) after treatment with bortezomib and lenalidomide. Here, a two‐stage Weibull method was used to adjust for the crossover of patients in the Hi DEX arm to pomalidomide‐based therapy. The adjusted difference in median OS between patients in the POM +Lo DEX and Hi DEX arms was 7· ...
Tópico(s): Cancer therapeutics and mechanisms
2014 - Wiley | British Journal of Haematology
Paul G. Richardson, David S. Siegel, Ravi Vij, Craig C. Hofmeister, Rachid Baz, Sundar Jagannath, Christine Chen, Sagar Lonial, Andrzej Jakubowiak, Nizar J. Bahlis, Kevin Song, Andrew Belch, Noopur Raje, Chaim Shustik, Suzanne Lentzsch, Martha Q. Lacy, Joseph Mıkhael, Jeffrey Matous, David H. Vesole, Min Chen, Mohamed H. Zaki, Christian Jacques, Zhinuan Yu, Kenneth C. Anderson,
Key Points Pomalidomide plus low-dose dexamethasone significantly improved PFS vs pomalidomide alone in relapsed and refractory multiple myeloma. Pomalidomide plus low-dose dexamethasone is an important new treatment option for RRMM patients who have received multiple prior therapies.
Tópico(s): Cancer Treatment and Pharmacology
2014 - Elsevier BV | Blood
Kevin Song, Meletios Α. Dimopoulos, Katja Weisel, Philippe Moreau, Antonio Palumbo, Andrew Belch, Stephen Schey, Pieter Sonneveld, Lars Sternås, Xiaoyan Yu, Ramesh Amatya, Mara Silvia Monzini, Mohamed H. Zaki, Christian Jacques, Jesús F. San Miguel,
Advances in treatments for multiple myeloma (MM) have resulted in improved survival. However, patients who have become refractory to novel agents have a poor prognosis, with a median overall survival (OS) of nine months, or as low as three months in the absence of further treatment after failure of
Tópico(s): Protein Degradation and Inhibitors
2014 - Ferrata Storti Foundation | Haematologica
Thierry Façon, Meletios Α. Dimopoulos, Angela Dispenzieri, John Catalano, Andrew R. Belch, Cyrille Hulin, Michèle Cavo, Antonella Pinto, Katja Weisel, Heinz Ludwig, Nizar J. Bahlis, Anne Banos, Mourad Tiab, Michel Delforge, James D. Cavenagh, Catarina Geraldes, Je‐Jung Lee, Christine I. Chen, Albert Oriol, Javier de la Rubia, Lugui Qiu, Darrell White, Daniel Binder, Kenneth C. Anderson, Philippe Moreau, Michel Attal, Robert Knight, Guang Chen, Jason Van Oostendorp, Christian Jacques, Annette Ervin‐Haynes, Lofti Benboubker,
Abstract Background Melphalan, prednisone and thalidomide (MPT) is a standard therapy for NDMM recognized worldwide based on a statistically significant advantage in overall survival (OS) and progression-free survival (PFS) vs. MP (Facon Lancet 2007; Fayers Blood 2011; NCCN 2013). The combination of lenalidomide and low-dose dexamethasone (Rd) increased OS with fewer adverse events (AEs) than treatment with lenalidomide and high-dose dexamethasone in NDMM pts (ECOG E4A03) (Rajkumar Lancet Oncol 2010). The ...
Tópico(s): Histone Deacetylase Inhibitors Research
2013 - Elsevier BV | Blood
Jesús F. San Miguel, Katja Weisel, Philippe Moreau, Martha Q. Lacy, Kevin Song, Michel Delforge, Lionel Karlin, Hartmut Goldschmidt, Anne Banos, Albert Oriol, Adrián Alegre, Christine Chen, Michèle Cavo, Laurent Garderet, Valentina Ivanova, Joaquín Martínez‐López, Andrew R. Belch, Antonio Palumbo, Stephen Schey, Pieter Sonneveld, Xin Yu, Lars Sternås, Christian Jacques, Mohamed H. Zaki, Meletios Α. Dimopoulos,
Background Few effective treatments exist for patients with refractory or relapsed and refractory multiple myeloma not responding to treatment with bortezomib and lenalidomide. Pomalidomide alone has shown limited efficacy in patients with relapsed multiple myeloma, but synergistic effects have been noted when combined with dexamethasone. We compared the efficacy and safety of pomalidomide plus low-dose dexamethasone with high-dose dexamethasone alone in these patients. Methods This multicentre, ...
Tópico(s): Protein Degradation and Inhibitors
2013 - Elsevier BV | The Lancet Oncology
Isabelle Giroux, Andréanne Faucher-Gravel, Alexandre St-Hilaire, Catherine Boudreault, Christian Jacques, Stéphane Bouchard,
The urge to gamble is a psychological, physiological, and emotional state involved in the maintenance of pathological gambling. The ability of repeated exposure to a virtual gambling environment to modify the urge to gamble and perceived self-efficacy (PSE) is investigated. Ten video lottery players move throughout a virtual bar with five video lottery terminals five times. The urge to gamble and PSE do not significantly vary during exposure to the gambling environment. However, the desire to gamble ...
Tópico(s): Gambling Behavior and Treatments
2013 - Mary Ann Liebert, Inc. | Cyberpsychology Behavior and Social Networking
Meletios Α. Dimopoulos, Katja Weisel, Kevin Song, Michel Delforge, Lionel Karlin, Hartmut Goldschmidt, Philippe Moreau, Anne Banos, Albert Oriol, Laurent Garderet, Michèle Cavo, Valentina Ivanova, Adrián Alegre, Joaquin Martínez‐López, Christine I. Chen, Andrew Spencer, Stefan Knop, Nizar J. Bahlis, Christoph Renner, Xin Yu, Kevin Hong, Lars Sternås, Christian Jacques, Mohamed H. Zaki, Jesús F. San Miguel,
Abstract Background RRMM patients (pts) who have exhausted novel agent treatment (Tx) have limited effective options and short overall survival (OS). The presence of high-risk cytogenetics predicts shorter OS (Kumar, 2012). POM is a distinct oral IMiD® immunomodulatory agent with direct anti-myeloma, stromal cell-support inhibitory, and immune modulatory effects (Quach, 2010). The US FDA approved POM for the Tx of pts with ≥ 2 prior Tx, including lenalidomide (LEN) and bortezomib (BORT), and progressive ...
Tópico(s): Cancer Treatment and Pharmacology
2013 - Elsevier BV | Blood
Antonio Palumbo, Roman Hájek, Michel Delforge, Martin Kropff, Maria Teresa Petrucci, John Catalano, Heinz Gisslinger, W Wiktor-Jędrzejczak, Mamia Zodelava, Katja Weisel, Nicola Cascavilla, Genadi Iosava, Michèle Cavo, Janusz Kłoczko, Joan Bladé, Meral Beksaç, Ivan Špıčka, Torben Plesner, J. Radke, Christian Langer, Dina Ben Yehuda, Alessandro Corso, Lindsay Herbein, Zhinuan Yu, Jay Mei, Christian Jacques, Meletios Α. Dimopoulos,
Lenalidomide has tumoricidal and immunomodulatory activity against multiple myeloma. This double-blind, multicenter, randomized study compared melphalan-prednisone-lenalidomide induction followed by lenalidomide maintenance (MPR-R) with melphalan-prednisone-lenalidomide (MPR) or melphalan-prednisone (MP) followed by placebo in patients 65 years of age or older with newly diagnosed multiple myeloma.We randomly assigned patients who were ineligible for transplantation to receive MPR-R (nine 4-week cycles ...
Tópico(s): Peptidase Inhibition and Analysis
2012 - Massachusetts Medical Society | New England Journal of Medicine
Paul G. Richardson, David S. Siegel, Rachid Baz, Susan L. Kelley, Nikhil C. Munshi, Jacob P. Laubach, Daniel M. Sullivan, Melissa Alsina, Robert Schlossman, Irene M. Ghobrial, Deborah Doss, Nora Loughney, Laura McBride, Elizabeth Bilotti, Palka Anand, Lisa Nardelli, Sandra Wear, Gail Larkins, Min Chen, M. Zaki, Christian Jacques, Kenneth C. Anderson,
Tópico(s): Peptidase Inhibition and Analysis
2012 - Elsevier BV | Blood
Meletios Α. Dimopoulos, Martha Q. Lacy, Philippe Moreau, Katja Weisel, Kevin Song, Michel Delforge, Lionel Karlin, Hartmut Goldschmidt, Anne Banos, Albert Oriol, Xin Yu, Lars Sternås, Christian Jacques, Mohamed H. Zaki, Jesús F. San Miguel,
Abstract Abstract LBA-6 Background: Multiple myeloma (MM) patients who have become refractory to bortezomib (BORT) and refractory or otherwise ineligible for thalidomide or lenalidomide (LEN) have a poor prognosis, with a median overall survival (OS) of 9 months (Kumar. Leukemia. 2012). There is no standard treatment available for these patients. Pomalidomide (POM) is a novel immunomodulatory drug that has shown activity in LEN- and BORT-refractory patients (Vij. ASCO 2012). MM-003 is an open-label, multicenter, ...
Tópico(s): Histone Deacetylase Inhibitors Research
2012 - Elsevier BV | Blood
Antonio Palumbo, Zdeněk Adam, Martin Kropff, Robin Foà, John Catalano, Heinz Gisslinger, W Wiktor-Jędrzejczak, Michel Delforge, Katja Weisel, Nicola Cascavilla, Jan Van Droogenbroeck, Genadi Iosava, Michèle Cavo, Joan Bladé, Meral Beksaç, Ivan Špıčka, Torben Plesner, Zhinuan Yu, Lindsey Herbein, Jay Mei, Christian Jacques, Meletios Α. Dimopoulos,
Abstract Abstract 475FN2 Background: An IMiDs® immunomodulatory agent, Len has a dual mechanism of action: its tumoricidal effect directly leads to tumor cell death, and its immunomodulatory effect may keep the tumor in remission. A phase 3, randomized, placebo (Pbo)-controlled trial, MM-015 compares MPR-R with fixed-duration MPR and MP induction in transplant-ineligible NDMM pts. Interim results showed unprecedented reduction in disease progression risk with MPR-R (Palumbo et al, IMW 2011); this ...
Tópico(s): Cancer therapeutics and mechanisms
2011 - Elsevier BV | Blood
Antonio Palumbo, Michel Delforge, John Catalano, Roman Hájek, Martin Kropff, Maria Teresa Petrucci, Zhinuan Yu, Lindsey Herbein, Jay Mei, Christian Jacques, Meletios Α. Dimopoulos,
Abstract Abstract 622 Background: Lenalidomide is an oral IMiD® compound with a dual mechanism of action, namely tumoricidal and immunomodulatory activity, and has proven efficacy in patients with MM. The current study (MM-015) is a prospective, randomized phase 3 trial designed to evaluate the efficacy and safety of continuous lenalidomide treatment (MPR-R: melphalan, prednisone, and lenalidomide induction followed by lenalidomide maintenance) vs fixed-duration regimens of melphalan and prednisone ( ...
Tópico(s): Protein Degradation and Inhibitors
2010 - Elsevier BV | Blood